Fibrinogen Concentrates

1. Coherent Market Insights Embolus is a blood product that clots and gathers in veins. Typically, fibrinogen concentrates are used to treat the condition. Fibrinogen is a protein made by the human body, in the uterine wall. Fibrinogen is produced in the liver and the blood. It acts as a coagulant and thickener in the blood. Fibrinogen is used primarily to treat thrombotic thrombosis, a condition that occurs when blood flow to a vein is blocked, usually due to past injury or surgery. Fibrinogen may also be used in the treatment of other conditions, such as those that cause a decrease in blood flow, such as deep vein thrombosis, a condition that can lead to major problems such as pulmonary embolism and heart attack. Fibrinogen can be derived from animal sources like pigs and cows. In recent years, however, there have been attempts to use this protein for treating several diseases. The most successful of these attempts has been the development of fibrinogen concentrates intended for use in the treatment of embolus, a type of blood product that clots and collects in veins. Several trials, however, have failed to demonstrate that these products improve the success rates of animal source fibrinolytic therapies. One of the most common uses for fibrinogen concentrates is in the process of "aggravation" or thrombotic therapy, in which blood is drawn and infused back into the body after a massive transfusion. Because the initial amount of blood may be too high, especially in cases such as traumatic injuries, or in patients undergoing dialysis, the resultant rise in circulating blood can cause severe discomfort. A method of "aggravation" was first used in the treatment of shock with the aid of a cryoprecipitate, or a solution that crystallizes the blood. While this method had been successful in many cases, it had serious drawbacks such as a lack of control over the amount of blood that was extracted, and the danger of bleeding. This is why, until recently, it was not feasible to use a large volume of a cryoprecipitate on an individual, such as after a massive transfusion. Read More : https://bit.ly/3guuyIK Coherent Market Insights